Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.

[1]  S. Pignata,et al.  Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): Activity and safety results of the MITO-2 randomized multicenter trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  V. Torri,et al.  A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis , 2008, British Journal of Cancer.

[3]  J. Dancey,et al.  Report of first-stage accrual for NCI 5886, a phase II study of erlotinib, carboplatin and paclitaxel as first-line treatment of ovarian cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Cannistra,et al.  Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Bookman,et al.  GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Kimmig,et al.  Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationau , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Dimopoulos,et al.  Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  P. Viens,et al.  A phase IB, open label, safety and pharmacokinetic (PK) study of escalating doses of PTK787/ZK 222584 (PTK/ZK) in combination with paclitaxel and carboplatin in patients (Pts) with stage IC to IV epithelial ovarian cancer (EOC). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Sabbatini,et al.  A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced stage ovarian, primary peritoneal, and fallopian tube cancer , 2005 .

[10]  I. Vergote,et al.  First line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIb-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A Gynecologic Cancer Intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression free survival , 2004 .

[11]  T. Bauknecht,et al.  A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. , 2003, Journal of the National Cancer Institute.

[12]  Robert S Mannel,et al.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Dimopoulos,et al.  37 Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer (AOC): long-term efficacy results , 2003 .

[14]  H. V. van Houwelingen,et al.  Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Piccart,et al.  Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. , 2000, Journal of the National Cancer Institute.

[16]  E. Partridge,et al.  A phase I study of paclitaxel, doxorubicin, and cisplatin in patients with previously untreated epithelial ovarian cancer. , 1998, Gynecologic oncology.

[17]  Mcguire Wp,et al.  Chemotherapy of advanced ovarian cancer. , 1998 .

[18]  J. Moore,et al.  Taxane/platinum/anthracycline combination therapy in advanced epithelial ovarian cancer. , 1997, Seminars in oncology.

[19]  R. Ozols,et al.  Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  E. Partridge,et al.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, The New England journal of medicine.

[21]  M. Gore,et al.  Impact of doxorubicin on survival in advanced ovarian cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  P. Kenemans,et al.  High-dose intensity regimens with epirubicin in ovarian cancer. , 1994, Seminars in oncology.

[23]  J. Fanning,et al.  Meta-Analysis of Cisplatin, Doxorubicin, and Cyclophosphamide Versus Cisplatin and Cyclophosphamide Chemotherapy of Ovarian Carcinoma , 1992, Obstetrics and gynecology.

[24]  E Wiltshaw,et al.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Roger W. Jelliffe,et al.  Creatinine Clearance: Bedside Estimate , 1973 .

[26]  P. Neven,et al.  Improving outcome in the first-line management of advanced ovarian cancer , 2007 .

[27]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.